Kalm Therapeutics Company Profile
Background
Overview
Kalm Therapeutics, founded in 2022, is a biotechnology company headquartered in Huntsville, Alabama. The company specializes in developing innovative, natural treatments for inflammatory skin conditions, with a primary focus on eczema and psoriasis. Their flagship product, the Kalm Patch, is a prescription patch designed to provide continuous, non-steroidal therapy for these conditions.
Mission and Vision
Kalm Therapeutics is committed to revolutionizing the treatment of inflammatory skin diseases by offering safe, effective, and natural alternatives to traditional therapies. Their mission is to develop natural medicines with clinical validation for chronic diseases, aiming to calm the immune response through gentler mechanisms than common immune suppressants.
Industry Significance
The company addresses a significant unmet need in dermatology by providing a non-steroidal, once-a-day treatment option for eczema and psoriasis. This approach offers patients a safer and more convenient alternative to traditional treatments, potentially improving adherence and quality of life.
Key Strategic Focus
Core Objectives
Kalm Therapeutics aims to develop and commercialize natural, non-steroidal treatments for chronic inflammatory skin conditions, focusing on patient safety, efficacy, and convenience.
Areas of Specialization
The company specializes in dermatological treatments, particularly for eczema and psoriasis, utilizing continuous dose technology to deliver therapeutic agents over extended periods.
Key Technologies Utilized
Kalm Therapeutics employs proprietary continuous dose technology in their Kalm Patch, which delivers a steady stream of anti-inflammatory, natural medication over 24 hours. This technology ensures optimal efficacy and patient compliance.
Primary Markets Targeted
The primary markets targeted by Kalm Therapeutics include the United States and other regions with high prevalence rates of eczema and psoriasis, focusing on both pediatric and adult populations.
Financials and Funding
Funding History
Kalm Therapeutics has raised a total of $700,000 across one funding round. The most recent funding activity was a seed round of $700,000 completed in July 2024.
Notable Investors
Specific details about individual investors are not publicly disclosed.
Utilization of Capital
The capital raised is intended to support the development and commercialization of the Kalm Patch, including clinical trials, regulatory approvals, and market entry strategies.
Pipeline Development
Key Pipeline Candidates
- Kalm Patch: A prescription patch designed to provide continuous, non-steroidal therapy for eczema and psoriasis.
Stages of Development
The Kalm Patch is in the clinical development stage, with ongoing efforts to advance its efficacy and safety profiles.
Target Conditions
The primary target conditions are eczema and psoriasis, focusing on providing a natural alternative to traditional treatments.
Anticipated Milestones
Kalm Therapeutics is approaching several major milestones in its pipeline, including advancing the clinical development of its experimental patch therapy for inflammatory skin diseases.
Technological Platform and Innovation
Proprietary Technologies
The company's proprietary continuous dose technology enables the Kalm Patch to deliver a steady stream of anti-inflammatory, natural medication over 24 hours, offering a non-steroidal alternative to traditional treatments.
Significant Scientific Methods
Kalm Therapeutics employs continuous dose technology to provide a controlled release of therapeutic agents, enhancing treatment efficacy and patient compliance.
Leadership Team
Executive Profiles
- AJ Singhal, M.S.: Founder and Chief Executive Officer. With over 20 years of biotech experience, Mr. Singhal has led teams developing new classes of antibacterials, antivirals, anticancer, and anti-inflammatory compounds. He is the lead inventor and PI on the NIH-funded eczema patch program that Kalm Therapeutics is based on.
- Dr. Tomoko Maeda-Chubachi, M.D., Ph.D.: Chief Medical Officer. Dr. Maeda-Chubachi brings extensive experience in dermatology and clinical research, contributing to the company's medical strategy and clinical development.
- Dr. Tacey Viegas, BPharm., Ph.D.: Chief Development Officer. Dr. Viegas has over 25 years of experience in pharmaceutical drug development, leading discovery and development activities for therapeutic agents in various areas, including dermatology.
Leadership Changes
In November 2025, Dr. Peter Lio, a Harvard-trained dermatologist and researcher, joined Kalm Therapeutics as both an investor and a member of its Scientific Advisory Board, marking a significant step as the company advances its clinical pipeline.
Competitor Profile
Market Insights and Dynamics
The dermatological treatment market, particularly for eczema and psoriasis, is substantial, with a growing demand for non-steroidal, natural alternatives to traditional therapies. This trend is driven by patient concerns over the side effects of long-term steroid use and a preference for natural treatment options.
Competitor Analysis
Kalm Therapeutics faces competition from established pharmaceutical companies and emerging biotech firms developing treatments for inflammatory skin conditions. Notable competitors include Incyte, LEO Pharma, Formation Bio, Arcutis, and DermBiont.
Strategic Collaborations and Partnerships
The addition of Dr. Peter Lio to the Scientific Advisory Board in November 2025 enhances Kalm Therapeutics' clinical expertise and strategic direction, supporting the advancement of its clinical pipeline.
Operational Insights
